All In Biotech

Drug Trial Radar · NCT01829711

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia

Last checked: Nov 20, 2026Latest source record: Apr 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

80

Actual

Start

Apr 29, 2013

Primary completion

May 24, 2017

Study completion Apr 29, 2019

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: \- Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets CD22, a molecule on the surface of essentially all hairy cell leukemia cells. Moxetumomab pasudotox binds to CD22, goes into the cell, and releases a toxin which kills the cell. In a phase I trial it had activity in relapsed/refractory hairy cell leukemia with safety profile supporting further clinical study (http://ncbi.nlm.nih.gov/pubmed/22355053). This is a phase III multicenter trial designed to confirm these results.

Conditions

  • Leukemia, Hairy Cell

Interventions

  • Moxetumomab pasudotoxDrug

  • IV Bag Protectant for Moxetumomab pasudotoxDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Durable Complete Response (CR) Assessed by Blinded Independent Central ReviewTime frame: Full disease assessment (CBC, bone marrow and imaging) at end of treatment (EOT; up to 24 weeks) and post EOT Day 181; CBC monthly for 6 months post EOT, every 3 months post Day 181 for first 2 years and every 6 months thereafter (approximately 6 years)
  2. Percentage of Participants With Durable CR by Investigator's AssessmentTime frame: Full disease assessment (CBC, bone marrow and imaging) at end of treatment (EOT; up to 24 weeks) and post EOT Day 181; CBC monthly for 6 months post EOT, every 3 months post Day 181 for first 2 years and every 6 months thereafter (approximately 6 years)

Locations

34 sites in 14 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California

  • Research Site

    Los Angeles, California

  • Research Site

    Miami, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Baltimore, Maryland

  • Research Site

    Bethesda, Maryland

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    New York, New York

  • Research Site

    Houston, Texas

  • Research Site

    Antwerp, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Brno, Czechia

  • Research Site

    Caen, France

  • Research Site

    Le Chesnay, France

  • Research Site

    Pessac, France

  • Research Site

    Pierre-Bénite, France

  • Research Site

    Rouen, France

  • Research Site

    Strasbourg, France

  • Research Site

    Berlin, Germany

  • Research Site

    Giessen, Germany

  • Research Site

    Heidelberg, Germany

  • Research Site

    Dublin, Ireland

  • Research Site

    Haifa, Israel

  • Research Site

    Bologna, Italy

  • Research Site

    Genova, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Siena, Italy

  • Research Site

    Bergen, Norway

  • Research Site

    Gdansk, Poland

  • Research Site

    Lodz, Poland

  • Research Site

    Belgrade, Serbia

  • Research Site

    Barcelona, Spain

  • Research Site

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.